HCPCS Code J0586: Injection, AbobotulinumtoxinA, 5 Units

## **Documentation requirements** Providers must document both the medical necessity and the specific administration details when billing HCPCS code J0586 for injection abobotulinumtoxinA, 5 units. According to a provider policy guide, the medical record should include a detailed history and/or physical exam, specialty consultation notes, and a clearly stated diagnosis (such as cervical dystonia, lower limb spasticity, muscle spasms, or a relevant central nervous system condition such as multiple sclerosis or stroke) (UM Criteria Subcommittee, 2024). It must also specify the injection site, the units administered, and whether the administration is therapeutic rather than for cosmetic purposes, which Medicare and Medicaid typically do not cover. Including this clinical justification helps support insurance payment and reduces the likelihood of claim denials due to insufficient documentation.

## **J0586 billing requirements** - **Bill per unit administered**: Each 5-unit increment of abobotulinumtoxinA (Dysport) is billed under HCPCS code J0586. Providers should report the number of units administered. For example, a 500-unit vial equals 100 billing units, and a 300-unit vial equals 60 billing units (Ipsen Biopharmaceuticals, Inc., n.d.). - **Include appropriate procedure codes**: Always include the relevant CPT codes describing the injection site (e.g., cervical dystonia, spasticity) alongside J0586, as required by coding guidelines (Centers for Medicare & Medicaid Services, n.d.). Examples include CPT codes such as 64612 or 64615, depending on muscle groups involved (e.g., cervical dystonia or spasticity of upper limbs). Selecting the most accurate CPT code corresponding to the injected muscle improves claim accuracy. - **List ICD-10 diagnosis codes**: Use the most specific ICD-10-CM diagnosis code that reflects the underlying condition (e.g., G24.3 for cervical dystonia, G83.40 for hemiplegia due to stroke). Precise diagnosis coding improves claims processing and payer acceptance under federal regulations. - **Track and report wastage if applicable**: If the vial is split between multiple patients, document both the units administered and any unused remainder as wastage per Medicare policy. Wastage may be billed with the JW modifier to report discarded or unused drug quantities, while administered units without wastage should be reported using the JZ modifier. Proper use of these modifiers is critical to comply with Medicare policy and avoid claim denials; always verify payer-specific requirements. - **Use correct revenue code and claim form fields**: In the physician office setting, report J0586 on CMS-1500 forms. For hospital outpatient settings, use CMS-1450, and assign revenue code 0636 for drugs requiring detailed coding (or 0250 for general pharmacy if the payer does not recognize 0636). - **Payer policy variations**: Coverage, prior authorization requirements, and billing rules for J0586 may vary between Medicare, Medicaid, private insurers, and Medicare Advantage plans. Providers should confirm specific payer policies before billing to ensure compliance and reimbursement.

## **Other relevant codes** - **64615**: Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral - **J0585**: Injection, onabotulinumtoxinA, 1 unit (Botox)

## **References** Centers for Medicare & Medicaid Services. (n. d.). Article - Billing and Coding: Botulinum toxins (A52848). https://www.cms.gov/medicare-coverage-database/view/article.aspx?DocID=L33646&LCDId=33646&articleId=52848 Ipsen Biopharmaceuticals, Inc. (n.d.). Reimbursement resource guide - Dysport (AbobotulinumtoxinA). https://www.dysport.com/sites/g/files/kcxpwu236/files/2022-04/DYS-US-005869-Dysport-Resource-Guide.pdf UM Criteria Subcommittee. (2024). AbobotulinumToxinA (Dysport) clinical coverage criteria. https://www.chpw.org/wp-content/uploads/content/provider-center/policies/AbobotulinumtoxinA_Dysport_Clinical_Coverage_Criteria_-_PM192.pdf